title: [Outcome of patients with clinically acute massive pulmonary embolism].
abstract: Acute massive pulmonary embolism (AMPE) is an event that places the recipient at an unusually high risk of sudden death. Among 183 patients with thromboembolic disease, AMPE has been diagnosed clinically in 58 cases (32%). Diagnostic criteria: cardiac arrest (24 cases--41%), shock (12--21%) acute cor pulmonale (ACP 15--26%) and ACP with shock (7 cases--12%). There were 33 women and 25 men aged 22-88 years in this group. In 25 patients heparin (H), in 7 streptokinase (S), in 1 tPA, in 7 S after H have been used, 26 patients (45%) survived, 32 (55%) died: there were 20 sudden deaths. Advanced underlying cardiopulmonary diseases or/and recurrent pulmonary embolism seem to be the most important predictors of fatal outcome of AMPE.
authors.affiliation: Kliniki Chorób Wewnetrznych, Instytutu Gruźlicy i Chorób Płuc w Warszawie.
authors.forename: S
authors.initials: S
authors.lastname: Filipecki
authors.forename: W
authors.initials: W
authors.lastname: Tomkowski
authors.forename: B
authors.initials: B
authors.lastname: Hajduk
authors.forename: J
authors.initials: J
authors.lastname: Burakowski
authors.forename: A
authors.initials: A
authors.lastname: Radomyski
authors.forename: B
authors.initials: B
authors.lastname: Vertun
mesh_terms: D000208:Acute Disease; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D011655:Pulmonary Embolism / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality; D013300:Streptokinase / Q000627:therapeutic use; D015996:Survival Rate; D015912:Thrombolytic Therapy; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D006493:Heparin; D013300:Streptokinase; D010959:Tissue Plasminogen Activator
vernacular_title: Losy chorych z klinicznie ostrym masywnym zatorem tetnicy płucnej.